Table 3.

Diagnostic performance of CEUS by perfusion type, enhancement homogeneous, hilum absent, and perfusion defect for the detection of CLNM from PTC patients.

Index	Sensitivity (95% CI)	Specificity (95% CI)	AUC (95% CI)	NLR (95% CI)	PLR (95% CI)	DOR (95% CI)
Perfusion type	0.95 (0.91–0.97)	0.87 (0.69–0.96)	0.96 (0.94–0.98)	0.06 (0.03–0.10)	7.51 (2.80–20.14)	124.17 (42.78–360.46)
Enhancement homogeneous	0.83 (0.70–0.91)	0.60 (0.51–0.68)	0.73 (0.69–0.77)	0.28 (0.17–0.47)	2.07 (1.76–2.45)	7.33 (4.23–12.72)
Hilum absent	0.77 (0.68–0.84)	0.63 (0.44–0.78)	0.78 (0.74–0.81)	0.37 (0.27–0.51)	2.05 (1.33–3.14)	5.48 (2.85–10.53)
Perfusion defect	0.95 (0.89–0.98)	0.57 (0.52–0.61)	0.91 (0.88–0.93)	0.08 (0.04–0.20)	2.19 (1.96–2.46)	26.32 (10.51–65.91)

AUC, area under the curve; CEUS, contrast-enhanced ultrasound; CLNM, cervical lymph node metastasis; DOR, diagnostic odds ratio; NLR, negative likelihood ratio; PLR, positive likelihood ratio; PTC, papillary thyroid carcinoma.